FDA gives OK to Mesoblast for mesenchymal precursor cell production

11/20/2012 | Australian Life Scientist

Mesoblast and the FDA have reached an agreement regarding the production process for mesenchymal precursor cells to be used in late-stage clinical trials for the treatment of congestive heart failure and other conditions. The FDA and Mesoblast put in place a path for the possible commercial production of the company's cell therapy products.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY